Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Assets: 2014-2024

Historic Assets for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $294.8 million.

  • KalVista Pharmaceuticals' Assets was N/A to $294.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $294.8 million, marking a year-over-year change of. This contributed to the annual value of $235.4 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Assets is $294.8 million, which was up 83.31% from $160.8 million recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Assets peaked at $294.8 million during Q4 2024, and registered a low of $66.2 million during Q1 2021.
  • In the last 2 years, KalVista Pharmaceuticals' Assets had a median value of $160.8 million in 2024 and averaged $186.3 million.
  • In the last 5 years, KalVista Pharmaceuticals' Assets tumbled by 35.68% in 2021 and then increased by 24.86% in 2024.
  • KalVista Pharmaceuticals' Assets (Quarterly) stood at $75.4 million in 2020, then plummeted by 35.68% to $66.2 million in 2021, then reached $138.7 million in 2023, then climbed by 15.92% to $294.8 million in 2024.
  • Its Assets was $294.8 million in Q4 2024, compared to $160.8 million in Q4 2024 and $200.2 million in Q3 2024.